Valsartan ‘shows promise’ in hypertrophic cardiomyopathy
A phase 2 trial suggests early treatment may attenuate cardiac remodelling.
AusDoc brings you the latest news from the European Society of Cardiology Congress 2021.
Use of valsartan in patients with early hypertrophic cardiomyopathy (HCM) due to a pathogenic sarcomeric gene variant attenuates markers of cardiac remodelling, a trial shows.